Lifespan of COVID‐19 living guideline recommendations: A survival analysis
Clinical and Public Health Guidelines · 2024-09 · 1 (4)
DOI: 10.1002/gin2.12012 ↗Kurz gefasst
Leitlinie in der Zeitschrift Clinical and Public Health Guidelines, online erschienen am 31.08.2024. Verfasst von Emma McFarlane und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Institute for Health and Care Excellence Manchester UK. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
NICE has maintained a portfolio of coronavirus disease 2019 (COVID‐19) living guidelines since March 2020. Recommendations within these living guidelines are subject to continuous surveillance and updates in response to triggers. However, the lifespan of individual living guideline recommendations and features that may impact whether a recommendation becomes out of date sooner is unknown.
Objectives
This study describes the length of time NICE COVID‐19 living guideline recommendations have remained valid.
Methods
All guidelines within NICE's COVID‐19 portfolio were included to determine the lifespan of living guideline recommendations. Data were collected on all recommendations that had been developed, undergone surveillance or updated between 1 March 2020 and 31 August 2022. The initial publication date, decision to update and updated publication date were extracted. Updates were labelled as major changes in evidence synthesis or minor changes without a substantial change in the evidence base. Any recommendation that had not been updated or withdrawn was censored. Survival analysis (Kaplan–Meier curve) was carried out to determine the lifespan of recommendations.
Results
Overall, 26 COVID‐19 living guidelines and 1182 recommendations were included in the analysis. Living recommendations had a median survival time of 739 days (interquartile range [IQR]: 332, 781). Based on recommendation type, intervention recommendations had a shorter survival time (354 days, IQR: 312, 775) compared to diagnosis (368 days, IQR: 328, 795), patient experience (733 days, IQR: 345, 795) and service delivery (739 days, IQR: 643, 781). Within intervention type, pharmacological recommendations had the shortest survival time versus nonpharmacological recommendations (335 days, IQR: 161, 775 vs. 775 days, IQR: 354, 775). Updates were published an average of 29.12 days following a surveillance decision.
Conclusion
Within living guidelines, some recommendations need to be updated sooner than others. This study outlines the value of a flexible responsive approach to surveillance according to the pace of change and expectation of update triggers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Institute for Health and Care Excellence Manchester UK.
ORCID-Profile: Emma McFarlane
Zitieren
APA
McFarlane, E., Mercer, T., Sharp, S., Hunter, D., Kelley, K., Glen, F., & Majeed, M. (2024). Lifespan of COVID‐19 living guideline recommendations: A survival analysis. Clinical and Public Health Guidelines, 1(4). https://doi.org/10.1002/gin2.12012
Vancouver
McFarlane E, Mercer T, Sharp S, Hunter D, Kelley K, Glen F, et al. Lifespan of COVID‐19 living guideline recommendations: A survival analysis. Clinical and Public Health Guidelines. 2024;1(4). doi:10.1002/gin2.12012
BibTeX
@article{McFarlane2024,
author = {McFarlane, Emma and Mercer, Toby and Sharp, Steve and Hunter, Debra and Kelley, Kate and Glen, Fiona and Majeed, Maria},
title = {Lifespan of COVID‐19 living guideline recommendations: A survival analysis},
journal = {Clinical and Public Health Guidelines},
year = {2024},
volume = {1},
number = {4},
doi = {10.1002/gin2.12012}
}
EUVIMED